This paper examines accounting for research and development costs and specifically the treatment of those costs acquired in business combinations that are accounted for as in-process research and development (IPR&D). Both the SEC and the FASB expressed concerns over an increase in IPR&D costs immediately charged against earnings in purchase-type business combinations in the past decade. The AICPA formed an Emerging Issues Task Force to address these concerns and compiled a set of best practices with respect to recording and reporting IPR&D costs. With recent changes in accounting for business combinations and the treatment of goodwill created in acquisitions, readers of financial statements should be aware of the potential impact of IPR&D costs on reported earnings in the year of combination as well as in subsequent years. Examples of the reporting of IPR&D costs are drawn from recent business combinations in the biotechnology and pharmaceuticals industries.
Read full abstract